Monitoring Schistosome Hybrids Under Under Praziquantel Pressure
Sen_hybrids
Prevalence of Potential Schistosome Hybrids and Their Invasive Capacity Under Praziquantel Pressure in Northern Senegal
1 other identifier
observational
250
1 country
1
Brief Summary
The overall objective of this project is to examine and quantify the potential existence and impact on Praziquantel (PZQ) efficacy, of naturally occurring S. haematobium and S. bovis hybrid populations in northern Senegal. Schistosome hybrids may present vigor compared to their pure parental forms and hence, may be less sensitive to PZQ. We hypothesise that PZQ repeated treatment selects the hybrid schistosome populations.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 11, 2020
CompletedFirst Submitted
Initial submission to the registry
November 13, 2020
CompletedFirst Posted
Study publicly available on registry
November 19, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedNovember 19, 2020
September 1, 2020
12 months
November 13, 2020
November 13, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Change from baseline in prevalence and intensity of schistosome infection
Determine at the 1 month post treatment the cure rate (CR) of the treatments and Egg Reduction Rates (ERR).
December 31. 2020
Secondary Outcomes (1)
Hybrids tolerance to praziquantel
December 31, 2021
Interventions
A single treatment with a dose of 40 milligram/kilogram (mg/kg)
Eligibility Criteria
Northern Senegal Children
You may qualify if:
- Children between the initiation courses (CI) and elementary course second year (CE2)
- Absence of declared chronic pathologies that could impact the follow-up
- Be positive for S. haematobium infection during the selection period (excreting eggs)
- Residing in the study area during the 3 years of the follow-up
You may not qualify if:
- Absence of written informed consent or expressed refusal from the child
- Enrolled in another on going study, which implicates the administration of PZQ or tests another product.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Bruno SENGHOR
Dakar, 18524, Senegal
Related Publications (1)
Senghor B, Mathieu-Begne E, Rey O, Doucoure S, Sow D, Diop B, Sene M, Boissier J, Sokhna C. Urogenital schistosomiasis in three different water access in the Senegal river basin: prevalence and monitoring praziquantel efficacy and re-infection levels. BMC Infect Dis. 2022 Dec 29;22(1):968. doi: 10.1186/s12879-022-07813-5.
PMID: 36581796DERIVED
Biospecimen
Schistosome miracidia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 13, 2020
First Posted
November 19, 2020
Study Start
August 11, 2020
Primary Completion
July 31, 2021
Study Completion
December 31, 2022
Last Updated
November 19, 2020
Record last verified: 2020-09